This is a prospective, single-arm, open-label, multi-center, observational study to assess the acute safety and efficacy of MINI TREK RX 1.20 mm for enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions.
Study Type
OBSERVATIONAL
Enrollment
71
Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
Scripps Green Hospital
La Jolla, California, United States
Peninsula Regional Medical Center
Salisbury, Maryland, United States
Northern Michigan Hospital
Petoskey, Michigan, United States
The Christ Hospital
Cincinnati, Ohio, United States
Percentage of Participants With Procedure Success
Procedure success was defined as meeting all the following after single or multiple attempts: 1. Successful delivery of the MINI TREK RX 1.20 mm balloon to and across the target lesion, 2. Successful inflation and deflation with the MINI TREK RX 1.20 mm balloon, 3. No vessel perforation, no flow-limiting vessel dissection, no reduction in TIMI flow from baseline, and no clinically significant arrhythmias requiring medical treatment or device intervention following dilatation with the MINI TREK RX 1.20 mm balloon, and 4. Achieve a final TIMI flow grade of 3 at the conclusion of the PCI procedure for the lesion.
Time frame: On Day 0 (From the start to end of the interventional procedure)
Rate of Device Success
Device Success was defined as meeting all the following after single or multiple attempts: 1. Successful delivery of the MINI TREK RX 1.20 mm balloon to and across the target lesion, defined as achieving a final residual percent diameter stenosis of \< 50%, 2. Successful dilatation with the MINI TREK RX 1.20 mm balloon as defined by improvement in Minimal Lumen Diameter (MLD) based on core lab analysis, and 3. No vessel perforation, no flow-limiting vessel dissection, no reduction in TIMI flow from baseline, and no clinically significant arrhythmias that required medical treatment or device intervention following dilatation with the MINI TREK RX 1.20 mm balloon.
Time frame: On Day 0 (From the start to end of the interventional procedure)
Rate of Lesion Success
Lesion Success was defined as meeting all the following after single or multiple attempts: 1. Successful dilatation with any device(s), defined as achieving a final residual percent diameter stenosis of \< 50%, 2. No vessel perforation, no flow-limiting vessel dissection, no reduction in TIMI flow from baseline, and no clinically significant arrhythmias requiring medical treatment or device intervention following dilatation with any device(s), and 3. Achievement of a final TIMI flow grade of 3 at the conclusion of the PCI procedure for the lesion.
Time frame: On Day 0 (From the start to end of the interventional procedure)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rate of Individual Procedural Parameters
The following parameters were assessed by either an angiographic core laboratory or the investigator at the site * Vessel perforation * Flow-limiting vessel dissection * Development of thrombus in the target vessel * Balloon rupture * Clinically significant arrhythmias requiring medical treatment or device intervention
Time frame: On Day 0 (From the start to end of the interventional procedure)
Rate of Major Adverse Cardiac Event (MACE)
In-hospital MACE was defined as the composite of all deaths, myocardial infarction (MI), and clinically indicated target lesion revascularization (CI-TLR) by coronary artery bypass graft surgery (CABG) or PCI during the hospitalization for the index procedure
Time frame: In-Hospital (1 - 3 Days)
Rate of Target Lesion Failure (TLF)
In-hospital TLF was defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and CI-TLR by CABG or PCI during the hospitalization for the index procedure
Time frame: In-Hospital (1 - 3 Days)
Rate of Stent Thrombosis
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. Angiographic confirmation involves presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent and presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes that suggest acute ischemia; Typical rise and fall in cardiac biomarkers; Non-occlusive; Occlusive thrombus Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy is a pathological confirmation. Probable stent thrombosis is considered to have occur after intracoronary stenting in case of any unexplained death within the first 30 days or any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause
Time frame: In-Hospital (1 - 3 Days)